These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14758783)

  • 1. [Hypoglutamatergic hypothesis of schizophrenia: evidence from genetic studies].
    Itokawa M; Yoshikawa T
    Seishin Shinkeigaku Zasshi; 2003; 105(11):1349-62. PubMed ID: 14758783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia.
    Ramsey AJ
    Prog Brain Res; 2009; 179():51-8. PubMed ID: 20302817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
    Pietraszek M
    Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glutamatergic neurotransmission in schizophrenics].
    Bleich S; Bleich K; Wiltfang J; Maler JM; Kornhuber J
    Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S56-61. PubMed ID: 11533851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mice with genetically altered glutamate receptors as models of schizophrenia: a comprehensive review.
    Inta D; Monyer H; Sprengel R; Meyer-Lindenberg A; Gass P
    Neurosci Biobehav Rev; 2010 Mar; 34(3):285-94. PubMed ID: 19651155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant linkage and association between a functional (GT)n polymorphism in promoter of the N-methyl-D-aspartate receptor subunit gene (GRIN2A) and schizophrenia.
    Tang J; Chen X; Xu X; Wu R; Zhao J; Hu Z; Xia K
    Neurosci Lett; 2006 Nov; 409(1):80-2. PubMed ID: 17011703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia.
    Boks MP; Rietkerk T; van de Beek MH; Sommer IE; de Koning TJ; Kahn RS
    Eur Neuropsychopharmacol; 2007 Sep; 17(9):567-72. PubMed ID: 17250995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance.
    Cherlyn SY; Woon PS; Liu JJ; Ong WY; Tsai GC; Sim K
    Neurosci Biobehav Rev; 2010 May; 34(6):958-77. PubMed ID: 20060416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
    Heresco-Levy U
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biological basis of schizophrenia: new directions.
    Weinberger DR
    J Clin Psychiatry; 1997; 58 Suppl 10():22-7. PubMed ID: 9265913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families.
    Timms AE; Dorschner MO; Wechsler J; Choi KY; Kirkwood R; Girirajan S; Baker C; Eichler EE; Korvatska O; Roche KW; Horwitz MS; Tsuang DW
    JAMA Psychiatry; 2013 Jun; 70(6):582-90. PubMed ID: 23553203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.
    du Bois TM; Huang XF
    Brain Res Rev; 2007 Feb; 53(2):260-70. PubMed ID: 17014910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: relevance to schizophrenia.
    Steullet P; Neijt HC; Cuénod M; Do KQ
    Neuroscience; 2006 Feb; 137(3):807-19. PubMed ID: 16330153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.
    Rujescu D; Bender A; Keck M; Hartmann AM; Ohl F; Raeder H; Giegling I; Genius J; McCarley RW; Möller HJ; Grunze H
    Biol Psychiatry; 2006 Apr; 59(8):721-9. PubMed ID: 16427029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The glutamate hypothesis of schizophrenia].
    Hasan A; Malchow B; Falkai P; Schmitt A
    Fortschr Neurol Psychiatr; 2014 Aug; 82(8):447-56. PubMed ID: 25105431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
    Mouri A; Noda Y; Enomoto T; Nabeshima T
    Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.